Market Overview

Q1 Seasonality In The Pharma/Biotech Space: What It Is, Why It Happens And Who Is Affected

Q1 Seasonality In The Pharma/Biotech Space: What It Is, Why It Happens And Who Is Affected
Related NVO
Benzinga's Top Upgrades, Downgrades For December 6, 2017
The Week Ahead For December 4: The Biggest Catalysts, Conferences, And Investor Events
Novo Nordisk - Came For The Gap, Stayed For The Long Term (Seeking Alpha)
Related AGN
Wall Street's M&A Chatter From December 12: Fox-Disney, Repros Therapeutics-Allergan, Agrium-Macrofertil
Lightning Round: Jim Cramer Shares His Thoughts On Allergan, ETP, Cisco And More
Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism; shares down 10% after hours (Seeking Alpha)

Biotech investors may have noticed that the first quarter of the year is a bit sluggish for drug sales. They aren’t imagining things, according to Bernstein analyst Aaron Gal.

Bernstein analyzed a group of about 40 drugs and found that Q1 sales declined by about 7 percent compared to Q4 sales in the past three years.

Gal identified four primary drivers of the seasonal slump:

  • 1. Less drugs are utilized in Q1 because of managed care rejections due to patients switching plans or new utilization policies, as well as patients opting not to purchase prescription drugs because their out-of-pocket cost is too high.
  • 2. High deductibles for commercial plans can place a heavy burden on patients in Q1.
  • 3. Due to the Medicare coverage gap, the entire cost of the patients’ half of their high-priced drug bills between $3,700 and $8,000 is incurred in Q1.
  • 4. Roughly half of the drugs studied received price increases in Q1 2015 and two-thirds received price hikes in Q1 2016.

“The impact of the 1Q seasonality disproportionally [affects] names with U.S. exposures, especially with primary care and high price prescription drugs,” Gal says.

Related Link: Here's Why Wednesday Is The Next Big Catalyst For Puma Biotech

Bernstein says U.S. primary care companies such as Novo Nordisk A/S (ADR) (NYSE: NVO) and Allergan plc Ordinary Shares (NYSE: AGN) are impacted the most by the Q1 weakness. Specialty prescription drug stocks such as Biogen Inc (NASDAQ: BIIB), Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ: JAZZ) and Shire PLC (ADR) (NASDAQ: SHPG) also take a hit.

However, companies with heavy medical benefits products, such as Amgen, Inc. (NASDAQ: AMGN) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN), are typically not impacted by the Q1 slump.

Bernstein has Outperform ratings on Allergan, Biogen, Shire and Regeneron.

Latest Ratings for NVO

Dec 2017Bank of AmericaUpgradesNeutralBuy
Dec 2017Morgan StanleyUpgradesEqual-WeightOverweight
Sep 2017Bank of AmericaUpgradesUnderperformNeutral

View More Analyst Ratings for NVO
View the Latest Analyst Ratings

Posted-In: Aaron Gal BernsteinAnalyst Color Biotech Top Stories Analyst Ratings General Best of Benzinga


Related Articles (AMGN + AGN)

View Comments and Join the Discussion!